View Document Preview and Link Document Date: 2010-12-17 12:00:34 Open Document File Size: 84,50 KB Share Result on Facebook
City Geneva / / Company Novartis / / IndustryTerm treatment of leprosy / rehabilitation services / health services / leprosy-treatment services / molecular tools / pharmaceutical / social services / routine treatment services / leprosy services / community systems / / MedicalCondition control leprosy / HIV / disease / multibacillary leprosy / subclinical infection / paucibacillary leprosy / Hansen disease / neuritis / areas influencing leprosy / blister / acute erythema nodosum leprosum / Leprosy / / MedicalTreatment retreatment / vaccination / Chemotherapy / chemoprophylaxis / multidrug therapy / / Organization Health Assembly / World Health Organization / Sasakawa Memorial Health Foundation / International Federation of Anti-Leprosy Associations / Expert Committee / Novartis Foundation for Sustainable Development / EXECUTIVE BOARD / Nippon Foundation / Expert Committee on Leprosy / / Position Director-General / / Product dapsone / / RadioStation 2 WHO / / Technology diagnostic tests / Chemotherapy / / SocialTag 
EXECUTIVE BOARD 128th Session Provisional agenda item 4.13 EB128[removed]December 2010